



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) EP 0 552 405 B1

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
25.11.1998 Bulletin 1998/48

(51) Int. Cl.<sup>6</sup>: A61K 47/18

(21) Application number: 92114684.1

(22) Date of filing: 28.08.1992

(54) A percutaneous absorption promoter, a tape plaster and a method of promoting percutaneous absorption

Perkutaner Absorptionspromoter, Pflaster und Verfahren zur Förderung der Perkutanenabsorption  
Stimulateur d'absorption percutanée, pansement et méthode pour la stimulation de l'absorption percutanée

(84) Designated Contracting States:  
DE FR GB

(30) Priority: 24.01.1992 JP 34274/92

(43) Date of publication of application:  
28.07.1993 Bulletin 1993/30

(60) Divisional application:  
97114794.7 / 0 815 871

(73) Proprietor: LINTEC Corporation  
Tokyo (JP)

(72) Inventors:  
• Suzuki, Eiichi  
Urawa-shi, Saitama-ken (JP)  
• Okabe, Hideaki  
Urawa-shi, Saitama-ken (JP)  
• Saito, Takanori  
Misato-shi, Saitama-ken (JP)

(74) Representative:  
Türk, Gille, Hrabal  
Brucknerstrasse 20  
40593 Düsseldorf (DE)

(56) References cited:  
FR-A- 2 281 162 US-A- 4 732 892  
US-A- 4 980 378

- PATENT ABSTRACTS OF JAPAN vol. 011, no. 063 (C-406)26 February 1987 & JP-A-61 225 120 ( NITTO ELECTRIC IND. CO. LTD. )
- DATABASE WPIL Week 8910, Derwent Publications Ltd., London, GB; AN 89-07165110 & JP-A-1 022 817 (TERUMO CORP.)
- DATABASE WPIL Week 8425, Derwent Publications Ltd., London, GB; AN 84-15549825 & JP-A-59 082 310 (SHISEIDO KK)
- PATENT ABSTRACTS OF JAPAN vol. 009, no. 324 (C-320)19 December 1985 & JP-A-60 155 111 ( HISAMITSU SEIYAKU KK )
- DATABASE WPIL Week 9246, Derwent Publications Ltd., London, GB; AN 92-376271 & JP-A-4 275 234 (RINTECH)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 552 405 B1

## Description

The present invention relates to a novel percutaneous absorption promoter. More particularly, the present invention relates to a percutaneous absorption promoter having excellent ability of promoting percutaneous absorption of a pharmacologically active substance and excellent safety simultaneously, capable of delivering the desired pharmacologically active substance rapidly to the location of treatment or to all parts of the body through the circulating system and effective for curing various kinds of disease. The present invention relates also to a novel tape plaster comprising it and a novel method of promoting percutaneous absorption by utilizing it.

During the recent progress of medical treatment, transdermal therapeutic systems (TTS) have been developed to absorb percutaneously and deliver desired pharmacologically active substances to all parts of the body and thus to maintain the curing effect for a prolonged time. For example, transdermal therapeutic systems utilizing nitroglycerol or isosorbide dinitrate for curing angina pectoris, those containing clonidine for curing hypertonia and those containing estradiol for curing climacteric difficulties have actually been utilized.

However, even though these transdermal therapeutic systems show many advantages such as evasion of metabolism of the pharmacologically active substances at intestine and liver, reduction of side reactions and increased retention of the pharmacological effect, they have problem that, because skin essentially has the barrier function against invasion of foreign substances, only limited kinds of pharmacologically active substances can attain the concentration of the substances in blood high enough to show the pharmacological effect and the pharmacologically active substances which can be utilized for the transdermal therapeutic systems are naturally very limited.

Various methods have been tried to improve the percutaneous absorption of pharmacologically active substances. For example, pharmacologically active substances were modified to form prodrugs and complexes. Ionic pharmacologically active substances were utilized with use of iontophoresis. These methods have a problem that the actual administration requires detailed studies on the individual pharmacologically active substance and a long period of time and a large amount of investment are inevitably required. On the other hand, percutaneous absorption promoters which increase percutaneous absorption of pharmacologically active substances by decreasing the barrier property of skin have been actively developed. It is expected by using these percutaneous absorption promoters that various kinds of pharmacologically active substances can be utilized without much limitations.

As the percutaneous absorption promoters, following compounds, for example, have been utilized: polar solvents, such as dimethylsulfoxide, decylmethylsulfoxide, dimethylformamide and dimethylacetamide; cycloalkanes, such as azacycloheptan-2-one and 1-dodecylazacycloheptan-2-one; esters of carboxylic acids and alcohols, such as isopropyl myristate and isopropyl palmitate; glycols; surface active agents, such as sodium laurylsulfate and sodium dodecylsulfate; and derivatives of fatty acids, pyroglutamic acid and urea which are natural moisturizing agents of skin. These absorption promoters have problems that they do not always satisfy both of the promotion of the percutaneous absorption and safety, such as safety from toxicity and irritation, and that a long time is required to exhibit the pharmacological activity because of a long lag time in the percutaneous absorption of the pharmacologically active substances.


## SUMMARY OF THE INVENTION

The present invention accordingly has an object to provide a percutaneous promoter having excellent ability of promoting the percutaneous absorption of a pharmacologically active substance and excellent safety simultaneously, capable of delivering the desired pharmacologically active substance rapidly to the location of treatment or to all parts of the body through the circulating system and effective for curing various kinds of disease. Another object of the invention is to provide a tape plaster comprising it. Still another object of the invention is to provide a method of promoting percutaneous absorption by utilizing it.

Extensive investigations undertaken by the present inventors with the objects described above lead to a discovery that a derivative of amino acid having the formula [1] promotes percutaneous absorption of pharmacologically active substances remarkably and has excellent safety simultaneously. The present invention has been completed on the basis of the discovery.

Thus, the percutaneous absorption promoter of the invention comprises

- (a) a pharmaceutically active substance and
- (b) a derivative of an amino acid having the formula:



wherein

$\text{R}^1$  is an acyl group having 1 to 20 carbon atoms,

$\text{R}^2$  is a saturated or unsaturated linear aliphatic hydrocarbon group having 1 to 4 carbon atoms and

$\text{R}^4$  is a hydrogen atom, a methyl group, isopropyl group, 2-methylpropyl group or 1-methylpropyl group.

The tape plaster of the invention comprises an adhesive material comprising the percutaneous absorption promoter described above coated on a tape substrate.

The method of promoting percutaneous absorption of the invention comprises promoting percutaneous absorption of a pharmacologically active substance by applying the percutaneous absorption promoter described above in combination with the pharmacologically active substance to a patient locally and percutaneously.

Other and further objects, features and advantages of the invention will appear more fully from the following description.

#### BRIEF DESCRIPTION OF THE DRAWING

The invention will be described with reference to the accompanying drawing wherein Figure 1 shows change of accumulated permeation of indomethacin with time in the case where ethyl N-n-octanoylanthranilate was used as the derivative of anthranilic acid and in the case where no such derivative was added.

#### DETAILED DESCRIPTION OF THE INVENTION

The invention will be described in detail in the following.

The percutaneous absorption promoter of the invention comprises a derivative of an amino acid having the formula [1].

Examples of the acyl group having 1 to 20 carbon atoms as the substituent  $\text{R}^1$  in the formula [1] are: aliphatic acyl groups, such as formyl group, acetyl group, propanoyl group, butanoyl group, pentanoyl group, octanoyl group, decanoyl group, dodecanoyl group, tetradecanoyl group, palmitoyl group, stearoyl group, oleoyl group, acryloyl group and the like; aromatic acyl groups, such as benzoyl group, toluoyl group, salicyloyl group, cinnamoyl group, naphthoyl group, phthaloyl group, furoyl group, anisoyl group and the like; and the like other groups.

Preferable examples among the acyl groups described above are saturated and unsaturated aliphatic acyl groups having 1 to 20 carbon atoms. More preferable examples among them are saturated and unsaturated linear aliphatic acyl groups having 2 to 16 carbon atoms.

The substituent  $\text{R}^4$  in the formula [1] is a hydrogen atom, methyl group, isopropyl group, 2-methylpropyl group or 1-methylpropyl group, and preferably a hydrogen atom.

The derivatives of the amino acids are preferably compounds having the formula [1] wherein  $\text{R}^1$  is a saturated or unsaturated linear aliphatic acyl group having 2 to 16 carbon atoms and  $\text{R}^2$  is a saturated or unsaturated linear aliphatic hydrocarbon group having 1 to 4 carbon atoms and, more preferably, compounds having the formula [1] wherein  $\text{R}^1$  is a saturated or unsaturated linear aliphatic acyl group having 8 to 12 carbon atoms and  $\text{R}^2$  is a saturated or unsaturated linear aliphatic hydrocarbon group having 1 to 4 carbon atoms.

The derivatives of the amino acids may be any of L-isomers, D-isomers and racemic isomers.

Examples of the derivatives of the amino acids are: ethyl ester of N-butyrylglycine, methyl ester of N-dodecanoylglycine, ethyl ester of N-dodecanoylglycine, butyl ester of N-dodecanoylglycine, methyl ester of N-myristoylglycine, ethyl ester of N-myristoylglycine, butyl ester of N-myristoylglycine, ethyl ester of N-dodecanoylalanine, ethyl ester of N-dodecanoylvaline, ethyl ester of N-dodecanoylleucine, ethyl ester of N-dodecanoylisoleucine and the like.

The derivatives of the amino acids having the formula [1] can be prepared by various conventional methods.

An acyl group having 1 to 20 carbon atoms can be introduced as the substituent  $\text{R}^1$  of the amino group in the amino acid, for example, by the reaction of the amino acid with an acid halide having the desired number of carbon atoms. In this method, the amino group can be modified with the acyl group having 1 to 20 carbon atoms by dissolving the amino

acid to be modified in an aqueous solution containing a scavenger of a hydrogen halide like sodium hydroxide, then adding an aqueous solution of a carboxylic acid halide having 1 to 20 carbon atoms and an aqueous solution containing the scavenger of the hydrogen halide to the above solution and allowing the reaction to proceed.

The percutaneous absorption promoter is utilized in combination with pharmacologically active substances (a) and applied to a patient percutaneously and locally. The kind of the pharmacologically active substance is not particularly limited but suitable substances can be selected and utilized from the generally known pharmacologically active substances.

Examples of the pharmacologically active substance of component (a) are: steroid anti-inflammatory drugs, such as prednisolone; dexamethasone, hydrocortisone, fluocinolone acetonide, betamethasone varelata; betamethasone dipropionate and the like; non-steroid anti-inflammatory drugs, such as indomethacin, diclofenac, ibufenac, ibuprofen, ketoprofen, flufenamic acid, mefenamic acid, phenylbutazone, methyl salicylate and the like; antihistamic drugs, such as diphenhydramine, chlorpheniramine, promethazine, triphenylamine and the like; central nervous system acting drugs, such as chlorpromazine, nitrazepam, diazepam, phenobarbital, reserpine and the like; hormones, such as insulin, testosterone, methyltestosterone, progesterone, estradiol and the like; antihypertensive drugs, such as clonidine, reserpine, guanethidine sulfate and the like; cardiotonics, such as digitoxin, digoxin and the like; antiarrhythmic drugs, such as propranolol hydrochloride, procainamide hydrochloride, ajmaline, pindolol and the like; coronary vaso dilators, such as nitroglycerin, isosorbide dinitrate, erythritol tetranitrate, papaverine hydrochloride, nifedipine and the like; local anesthetics, such as lidocaine, benzocaine, procaine hydrochloride and the like; hypnotics and sedatives, such as barbitals, thiopental, phenobarbital, cyclobarbitals and the like; analgesics, such as morphine, aspirin, codeine, acetanilide, aminopyrine and the like; antibiotics, such as penicillin, tetracycline, erythromycin, streptomycin, gentamicin and the like; fungicides, such as benzalkonium chloride, acetophenylamine, nitrofurazone, pentamycin, naphthiomate and the like; anticancer drugs, such as 5-fluorouracil, busulfan, actinomycin, bleomycin, mitomycin and the like; diuretics, such as hydrochlorothiazide, perflutide, reserpine and the like; parasympatholytic drugs, such as scopolamine, atropine and the like; antiepileptics, such as nitrazepam, meprobamate and the like; antiparkinsonism drugs, such as chlorzoxazone, levodopa and the like; sulfa drugs, such as sulfamine, sulfamonomethoxine, sulfamethizole and the like; vitamins; prostaglandins; antispasm drugs; contraceptives and the like. Acidic pharmacologically active substances are preferable and acidic pharmacologically active substances having a carboxylic group are more preferable.

Examples of the acidic pharmacologically active substance having carboxylic group are ibuprofen, flurbiprofen, phenopropfen, diclofenac, ibufenac, mefenamic acid, flufenamic acid, salicylic acid, acetylsalicylic acid and the like. Examples of the acidic pharmacologically active substance having no carboxylic group are: phenylbutazone, ketophenylbutazone, oxyphenbutazone, phenobarbital, amobarbital, cyclobarbitals and the like.

The pharmacologically active substance can be used singly or as a combination of two or more kinds.

The percutaneous absorption promoter of the invention may be, according to desire, utilized in combination with various kinds of pharmacologically allowable additives, such as stabilizers, anti-aging agents, antioxidants, perfumes, fillers and other kinds of percutaneous absorption promoters.

The method of utilizing the percutaneous absorption promoter is not particularly limited. The promoter can be utilized in any form of conventionally utilized external preparations, such as ointments, creams, gels, lotions, liquids, sprays, cataplasmas, tape plasters and the like. The preferable form is tape plasters.

As the base of ointments and creams, fatty oils, lanolin, vaselin, paraffines, plastibases, glycols, higher fatty acids, higher alcohols and the like are utilized. If necessary, stabilizers, preservatives, emulsifiers, dispersants and the like may be added to the base. As the base of lotions, ethanol, glycerol, glycols and the like are utilized. As the base of liquids, ethanol, purified water, glycols and the like are utilized.

Examples of the base of cataplasmas are natural polymers, such as gelatin, sodium alginate, corn starch, tragacanth gum, casein and the like; celluloses, such as methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose and the like; starches, such as dextran, carboxymethyl starch and the like; and synthetic polymers, such as polyvinyl alcohol, sodium polyacrylate, polyvinyl pyrrolidone, polyvinyl ether and the like. If necessary, moisturizing agents, such as glycerol, propylene glycol and the like, inorganic fillers, such as kaolin, bentonite, zinc oxide and the like, thickness adjusting agents, pH adjusting agents and the like may be compounded to the base.

As the adhesive for tapes and patches, for example, acrylic adhesives, rubber adhesives, silicone adhesives and the like are utilized.

The adhesives can be made into microreservoir-type materials by dispersing the pharmacologically active substance or a mixture of the pharmacologically active substance and a water soluble polymer within the adhesives. Dispersion of adhesives containing the pharmacologically active substance within the base of cataplasma can also be utilized.

The acrylic adhesives comprise, as the main component thereof, at least one polymer selected from the group consisting of, for example, homopolymers of acrylic esters, copolymers comprising two or more kinds of acrylic ester units and copolymers of acrylic esters and other functional monomers.

Examples of the acrylic ester are butyl (meth)acrylate, pentyl (meth)acrylate, hexyl (meth)acrylate, heptyl

(meth)acrylat , octyl (meth)acrylate, nonyl (meth)acrylate, decyl (meth)acrylate and the like. Examples of the functional monomer are monomers containing a hydroxyl group, such as hydroxyethyl (meth)acrylate, hydroxypropyl (meth)acrylate and the like, and monomers containing an amide group, such as (meth)acrylamide, dimethyl (meth)acrylamide and the like.

5 The acrylic adhesives can be generally divided into solvent type adhesives and emulsion type adhesives. The solvent type adhesives generally comprise the acrylic polymer, solvents, crosslinking agents, adhesion promoters if desired and other ingredients. As the crosslinking system, the methylol group crosslinking system, the ionic crosslinking system, the urethane crosslinking system, the epoxy crosslinking system or the like are utilized.

The emulsion type adhesives generally comprise the acrylic polymer, emulsifiers, aqueous solvents, adhesion promoters if desired and other ingredients.

10 The rubber adhesives comprise, as the main components thereof, at least one polymer selected from the group consisting of, for example, natural rubber, polyisoprene rubber, polyisobutylene rubber, styrene-butadiene-styrene block copolymer and styrene-isoprene-styrene block copolymer.

Adhesion promoters, plasticizers, antioxidants, fillers and the like may be compounded with the rubber adhesives, if desired. The solvent type adhesives and the emulsion type adhesives using rubber latices are preferably utilized.

15 The silicone adhesives comprise, as the main components thereof, polydimethylsiloxane, polydiphenylsiloxane and the like. The solvent type adhesives comprising adhesive promoters, plasticizers, filler and the like are preferably utilized.

The adhesion promoters compounded with the adhesives according to the desire are, for example, natural resins, 20 such as rosin resins, polyterpene resins and the like, petroleum resins such as C<sub>5</sub> resins, C<sub>9</sub> resins, DCPD resins and the like and synthetic resins, such as coumarone-indene resins, xylene resins and the like.

The base utilized for the tape plasters are, for example, sheets and films of synthetic resins, such as polyester, polyvinyl chloride, polypropylene, polyethylene, polyurethane and the like, synthetic papers, sheets and films of cellulose, nonwoven fabrics, woven fabrics, knitted fabrics and the like.

25 The amount of application of the percutaneous absorption promoter of the invention can be suitably selected according to the mode and the condition of the application. It is generally in the range from 0.1 to 50 weight %, preferably in the range from 0.5 to 30 weight % based on the total amount of the transdermal therapeutic formulation comprising the percutaneous absorption promoter. When the percutaneous absorption promoter is utilized in tape plasters, the amount is in the range from 5 to 30 weight % on the same basis.

30 The amount of the pharmacologically active substance is preferably in the range from 0.5 to 20 weight %, more preferably in the range from 1 to 10 weight %, based on the total amount of the transdermal therapeutic formulation.

It is the general understanding that the barrier property of skin against foreign substances has the basis on the structure of stratum corneum. This is more easily understood when one observes remarkably increased penetration of pharmacologically active substances through skin when the surface of the skin is partially removed by some cause, for example by cleavage of tape attached to the skin. The stratum corneum of skin is composed of layers of keratin cells which are made of proteins of flattened structures. It is generally understood that there are two main routes of passage for pharmacologically active substances: the transcellular route which is the passage through cells and the intercellular route which is the passage through interstices between cells. The stratum corneum cells are composed of keratin and lipids and, at the intercellular route, lamella layers are formed by amphiphilic materials such as phospholipids and the like, thus hydrophilic layers and lipophilic layer being accumulated to form a multilayer area. In the hydrophilic layers, molecules of water aggregate together to form clusters. Both of the hydrophilic and lipophilic layers show high resistance against diffusion of foreign substances and it is generally understood that the barrier property of skin is caused by the tight structure of the skin layers as described here.

45 The derivatives of amino acids having the formula [1] have particularly high affinity to lipids and give fluctuations to the lipids, this condition being considered to cause decrease of the resistance against diffusion and increase of the permeation of the pharmacologically active substances. The derivatives of amino acids are considered to affect the structure of water molecule by the effect on the lipids as well, to cause increase of the permeation of the substances.

The percutaneous absorption promoter of the invention is a derivative of amino acids having the same backbone structure as that of the amino acids showing the function of vitamin L1, one of the vitamins found in the body. It is therefore decomposed to compounds harmless to the body by enzymes in the body, such as esterase, peptidase and the like.

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

55 The invention will be understood more readily with reference to the following examples; however, these examples are intended to illustrate the invention and are not to be construed to limit the scope of the invention.

Example of preparation of derivatives of glycine

## Example of preparation of material 1

To a solution of glycine in a 1 N-sodium hydroxide, an ether solution of n-dodecanoyl chloride and a 1 N-aqueous solution of sodium hydroxide were dropped simultaneously and the mixture was stirred for 1 hour. The reaction mixture was then neutralized with hydrochloric acid and ether was removed from the solution. N-n-dodecanoylglycine was obtained from the remaining reactant after the purification by column chromatography with the yield of 84.7 %. The melting point of the product was 115.5 to 116.7°C.

Thionyl chloride was dropped to ethanol and the mixture was stirred for 1 hour. Then, N-n-dodecanoylglycine was added to the mixture and reaction was allowed to proceed for 2 days at the room temperature. After the reaction, the solvent was removed and ethyl ester of N-n-dodecanoylglycine was obtained from the remaining reactant after the purification by column chromatography with the yield of 94.1 %. The melting point of the product was 42.1 to 43.2°C.

Various kinds of derivatives of glycine having the amino group modified with an acyl group and the carboxylic group moved with an alkyl group as shown in Table 1 were prepared by the similar methods to the above.

## Example of preparation of material 2

Derivatives of various amino acids having the carboxylic group modified with an alkyl group were prepared by the same method as in Example of preparation of material 1 except that the derivative of glycine having the amino group modified with the acyl group was replaced by one of the following compounds: N-n-dodecanoyl-L-alanine, N-n-dodecanoyl-L-valine, N-n-dodecanoyl-L-leucine and N-n-dodecanoyl-L-isoleucine.

## Example 1

Percutaneous permeability test

In a vertical Franz type cell, a piece of skin taken from abdomen of a Wistar rat was used as the permeation membrane. As the donor solution, a solution of indomethacin as the model pharmacologically active substance and a derivative of anthranilic acid (1 weight %, respectively) in a 50 % aqueous solution of ethanol was used. As the receiver solution of the permeation, a buffer solution of phosphoric acid of pH 7.2 was used. Concentration of the pharmacologically active substance in the receiver solution was measured with time by high performance liquid chromatography (HPLC).

Ratio of the peak areas of the pharmacologically active substance and the internal standard substance was obtained from the HPLC chart. The concentration of the pharmacologically active substance was obtained by using the calibration curve which had been made beforehand. (The method of internal standard)

Activity of promoting the percutaneous absorption was evaluated on the derivatives of the amino acids prepared in Example of preparation of material 1 by using indomethacin as the pharmacologically active substance. Results of the evaluation are shown in Table 1.

Table 1

derivative of glycine	permeation based on the control
ethyl ester of N-n-butanoylglycine	2.01
methyl ester of N-n-dodecanoylglycine	3.87
ethyl ester of N-n-dodecanoylglycine	5.19
n-butyl ester of N-n-dodecanoylglycine	4.97
methyl ester of N-n-tetradecanoylglycine	4.73
ethyl ester of N-n-tetradecanoylglycine	2.82
n-butyl ester of N-n-tetradecanoylglycine	4.04

The activity of promoting the percutaneous absorption of the pharmacologically active substances by the percutaneous absorption promoter of the invention can be examined, for example, by the in vitro diffusion test using a piece of

skin taken from abdomen of a rat. When indomethacin was used as the pharmacologically active substance, the activities of promoting the percutaneous absorption of the pharmacologically active substance by the percutaneous absorption promoters were found to be 5.19, 4.97, 4.73 and 4.04 for ethyl ester of N-n-dodecanoylglycine, n-butyl ester of N-n-dodecanoylglycine, methyl ester of N-myristoylglycine and n-butyl ester of N-myristoylglycine, respectively, based on the activity of the control. Thus it was found that the formulations using the percutaneous absorption promoters of the invention have activities more than four times higher than the formulation without them.

#### Example 2

Activities of promoting the percutaneous absorption of the derivatives of amino acids prepared in Example of preparation of material 2 were evaluated by using indomethacin as the pharmacologically active substance. Results are shown in Table 2.

Table 2

derivative of amino acid	result based on control
ethyl ester of N-n-dodecanoyl-L-alanine	2.57
ethyl ester of N-n-dodecanoyl-L-valine	2.16
ethyl ester of N-n-dodecanoyl-L-leucine	1.89
ethyl ester of N-n-dodecanoyl-L-isoleucine	2.44

#### Example 3

Activity of promoting the percutaneous absorption of ethyl ester of N-n-dodecanoylglycine prepared in Example of preparation of material 1 was evaluated by using indomethacin, sodium salicylate, ketoprofen, prednisolone and pindolol as the pharmacologically active substance.


Results were 5.19, 4.27, 1.52, 5.01 and 19.13 for indomethacin, sodium salicylate, ketoprofen, prednisolone and pindolol, respectively, based on the value of control.

To summarize the advantages obtained by the invention, the percutaneous promoter of the invention has excellent ability of promoting the percutaneous absorption of the pharmacologically active substances and excellent safety simultaneously, capable of delivering the desired pharmacologically active substances rapidly to the location of treatment or to all parts of the body through the circulating system and effective for curing various kinds of disease. The tape plaster comprising it and the method of promoting percutaneous absorption by utilizing it have the same advantages.

#### Claims

1. A percutaneous absorption promoter composition which comprises

- (a) a pharmaceutically active substance and
- (b) a derivative of an amino acid having the formula:




wherein

- R<sup>1</sup> is an acyl group having 1 to 20 carbon atoms,
- R<sup>2</sup> is a saturated or unsaturated linear aliphatic hydrocarbon group having 1 to 4 carbon atoms and
- R<sup>4</sup> is a hydrogen atom, a methyl group, isopropyl group, 2-methylpropyl group or 1-methylpropyl group.

2. The composition of claim 1, wherein R<sup>1</sup> is a saturated or unsaturated aliphatic acyl group having 1 to 20 carbon

atoms.

3. The composition of claim 1 or 2, wherein  $R^1$  is a saturated or unsaturated linear aliphatic acyl group having 2 to 16 carbon atoms.
4. The composition of any of claims 1 to 3, wherein  $R^4$  is a hydrogen atom.
5. The composition of any of claims 1 to 4 wherein the pharmaceutically active substance is selected from the group consisting of indomethacin, ketoprofen, prednisolone and pindolol.
6. A tape plaster which comprises an adhesive material and a percutaneous absorption promotor composition of any of claims 1 to 5 coated on a tape substrate.
7. Use of a derivative of an amino acid having the formula



wherein


- $R^1$  is an acyl group having 1 to 20 carbon atoms,  
 $R^2$  is a saturated or unsaturated linear aliphatic hydrocarbon group having 1 to 4 carbon atoms and  
 $R^4$  is a hydrogen atom, a methyl group, isopropyl group, 2-methylpropyl group or 1-methylpropyl group

as a percutaneous absorption promotor.

#### Patentansprüche

1. Promotorzusammensetzung der perkutanen Absorption, umfassend

- (a) eine pharmakologisch aktive Substanz und
- (b) ein Derivat einer Aminosäure der Formel:




worin

- $R^1$  eine Acylgruppe mit 1 bis 20 Kohlenstoffatomen ist,  
 $R^2$  eine gesättigte oder ungesättigte, lineare, aliphatische Kohlenwasserstoffgruppe mit 1 bis 4 Kohlenstoffatomen ist und  
 $R^4$  ein Wasserstoffatom, eine Methylgruppe, Isopropylgruppe, 2-Methylpropylgruppe oder 1-Methylpropylgruppe ist.
2. Zusammensetzung gemäß Anspruch 1, worin  $R^1$  eine gesättigte oder ungesättigte, aliphatische Acylgruppe mit 1 bis 20 Kohlenstoffatomen ist.
  3. Zusammensetzung gemäß Anspruch 1 oder 2, worin  $R^1$  eine gesättigte oder ungesättigte, lineare, aliphatische Acylgruppe mit 2 bis 16 Kohlenstoffatomen ist.



4. Zusammensetzung gemäß einem der Ansprüche 1 bis 3, worin R<sup>4</sup> ein Wasserstoffatom ist.
5. Zusammensetzung gemäß einem der Ansprüche 1 bis 4, worin die pharmaz utisch aktive Substanz gewählt wird aus der aus Indomethacin, Ket profen, Prednisolon und Pindolol bestehenden Gruppe.
6. Heftpflaster, welches ein Haftmaterial und eine Promotorzusammensetzung der perkutanen Absorption gemäß einem der Ansprüche 1 bis 5 beschichtet auf einem Streifensubstrat umfaßt.
7. Verwendung eines Derivates einer Aminosäure der Formel



worin


- R<sup>1</sup> eine Acylgruppe mit 1 bis 20 Kohlenstoffatomen ist,  
 R<sup>2</sup> eine gesättigte oder ungesättigte, lineare, aliphatische Kohlenwasserstoffgruppe mit 1 bis 4 Kohlenstoffatomen ist und  
 R<sup>4</sup> ein Wasserstoffatom, eine Methylgruppe, Isopropylgruppe, 2-Methylpropylgruppe oder 1-Methylpropylgruppe ist,

als einen Promotor der perkutanen Absorption.

#### Revendications

1. Composition stimulant l'absorption percutanée, qui comprend

- (a) une substance pharmaceutiquement active, et
- (b) un dérivé d'acide aminé de formule




dans laquelle

- R<sup>1</sup> est un groupe acyle en C<sub>1</sub> à C<sub>20</sub>.  
 R<sup>2</sup> est un groupe hydrocarboné aliphatique linéaire saturé ou insaturé en C<sub>1</sub> à C<sub>4</sub>, et  
 R<sup>4</sup> est un atome d'hydrogène, un groupe méthyle, un groupe isopropyle, un groupe 2-méthylpropyle, ou un groupe 1-méthylpropyle.

2. Composition de la revendication 1, dans laquelle R<sup>1</sup> est un groupe acyle aliphatique saturé ou insaturé en C<sub>1</sub> à C<sub>20</sub>.
3. Composition de la revendication 1 ou 2, dans laquelle R<sup>1</sup> est un groupe acyle aliphatique linéaire saturé ou insaturé en C<sub>2</sub> à C<sub>16</sub>.
4. Composition de l'une quelconque des revendications 1 à 3, dans laquelle R<sup>4</sup> est un atome d'hydrogène.
5. Composition de l'une quelconque des revendications 1 à 4, dans laquelle la substanc pharmaceutiquement active est choisie dans l groupe constitué par l'indométhacine, le kétoprofène, la prednisolone et le pindolol.

6. Pansement en ruban qui comprend un matériau adhésif et une composition stimulant l'absorption percutanée de l'une quelconque des revendications 1 à 5, sur un substrat en ruban.

7. Utilisation d'un dérivé d'acide aminé de formule



dans laquelle

R<sup>1</sup> est un groupe acyle en C<sub>1</sub> à C<sub>20</sub>.

R<sup>2</sup> est un groupe hydrocarboné aliphatique linéaire saturé ou insaturé en C<sub>1</sub> à C<sub>4</sub>, et

R<sup>4</sup> est un atome d'hydrogène, un groupe méthyle, un groupe isopropyle, un groupe 2-méthylpropyle, ou un groupe 1-méthylpropyle,

comme stimulateur d'absorption percutanée.

- (b) jusqu'à 99,8% en poids d'un diester propylèneglycolique des acides caprylique et caprique;  
(c) jusqu'à 15% en poids d'acide silicique.

2. Un procédé de fabrication d'une composition pharmaceutique pour l'administration transmembranaire de médicaments, caractérisé en ce que de 0,2 à 5% en poids d'un médicament, choisi parmi: diphenhydramine, tétrahydroaminoacridine, aténolol, tazifylline, 2-méthoxy-4-[2-(5-méthyl-1H-pyrazol-3-yl)éthényl]phénol ou un de leurs sels pharmaceutiquement acceptables, est combiné avec jusqu'à 99,8% en poids d'un diester propylèneglycolique des acides caprylique et caprique et jusqu'à 15% en poids d'acide silicique.

10

**Revendication pour les Etats contractants suivants : ES, GR**

1. Un procédé de fabrication d'une composition pharmaceutique pour administration transmembranaire de médicaments, caractérisé en ce que de 0,2 à 5% en poids d'un médicament, choisi parmi: diphenhydramine, tétrahydroaminoacridine, aténolol, tazifylline, 2-méthoxy-4-[2-(5-méthyl-1H-pyrazol-3-yl)éthényl]phénol ou un de leurs sels pharmaceutiquement acceptables, est combiné avec jusqu'à 99,8% en poids d'un diester propylèneglycolique des acides caprylique et caprique et jusqu'à 15% en poids d'acide silicique.

20

25

30

35

40

45

50

55

**THIS PAGE BLANK (US:70)**